DNAprint Genomics (DNAG)

[SlopsterSlasher]

By: worktoplay
08 Jul 2004, 11:33 PM EDT
Msg. 304755 of 304844
(This msg. is a reply to 304741 by terryhallinan.)
Jump to msg. #
terry...Speculation...

Are these events related in any way?

http://biz.yahoo.com/bw/040422/226216_1.html

Sun City Industries Enters into Reorganization Agreement with China Based Biotech & Pharmaceutical Company

Thursday April 22, 10:16 pm ET

Agreement Signed With Yangling Daiying Biological Engineering Co., Ltd.

APOPKA, Fla.--(BUSINESS WIRE)--April 22, 2004-- Sun City Industries, Inc. (OTCBB: SCII - News) has entered into a Reorganization Agreement with Yangling Daiying Biological Engineering Co., Ltd., a corporation organized under the laws of the People's Republic of China. Daiying has developed the world's very first Hepatitis C virus (HCV) culture that retains biological activity in vitro. The Reorganization Agreement is conditional upon the signing of a consulting agreement, warrant agreement and the completion of various schedules to be part of the Reorganization Agreement. A closing date has not yet been set but the parties are striving to close in April 2004. Sun City will be filing an 8K to satisfy its reporting requirements under Regulation FD and the Exchange Act of 1934 as amended. The Reorganization Agreement will be provided as an exhibit to the 8K.

And this:

http://www.prbpharmaceuticals.com/news/attachment/Lai_release.pdf

Dr. Lai has also been at the forefront of research on the hepatitis C virus. He lead the scientific team that discovered that the hepatitis virus can mimic one of the molecular targets of interferon, the body’s naturally occurring antiviral agent, blocking its ability to kill viruses. This finding has served as a cornerstone of research to develop effective therapies to combat hepatitis C.

I only mention it because of this:

http://www.prbpharmaceuticals.com/company/management.asp

Hector J. Gomez, M.D., Ph.D., Chief Medical Officer, Head of Research and Development.

Dr. Gomez has over twenty years of experience in the biopharmaceutical industry. From 1994-1999, as President and CEO of Transcend Therapeutics, a biotechnology company in Cambridge, MA, Dr. Gomez defined its strategic planning and oversaw its implementation. He led the transition from a private to a public company (IPO). He was also CEO of Zengen, Inc., a private Biotech Company in California. Before joining Transcend, he was Vice President of Medical Affairs for Vertex Pharmaceuticals in Cambridge, MA, where he was responsible for planning and implementing the Pre-Clinical, Clinical Research and Regulatory Affairs departments. Prior to that he was a senior executive for two large pharmaceutical companies: Executive Director, Cardiovascular for Ciba-Geigy in Summit, NJ, and before that, Senior Director, Cardiovascular Clinical Research for Merck in Rahway, NJ. Dr. Gomez received an M.D. from the National University of Colombia, and a Ph.D. from Marquette University and a Diploma in Clinical Pharmacology from Tulane University.

Most of the management of PRBPharmaceuticals were at one time associated with Zengen, a privately held California Biotech company conducting research into novel peptides. Dr. Gomez was at one time the CEO of Zengen. Interestingly, he was only CEO for about a six month period, and then left there. The month he left, he founded GemBiomics LLC with Richard Gabriel. A month after that he was named to DNAPrint's BOD. Some time in 2003 he reuinited with many of the former principals involved with Zengen, and became CMO of PRB (right around the time he was named CMO of DNAPrint).

Later,
W2P